Guinea-Bissau
Guinea-Bissau has halted a US-backed hepatitis B vaccine study on newborns, pending an emergency ethical review. The country’s health minister says a six-member ethics committee never met before the study was approved, a major red flag.
The trial would randomly vaccinate some newborns and withhold the shot from others, tracking illness, death, and development. Critics say that’s unethical, because the vaccine is proven to protect babies in a country where hepatitis B is common.
Africa CDC leadership supports the review, saying decisions must serve African public health, not outside interests.
But US health officials insist the study is still moving forward. The project is funded by a $1.6 million no-bid US contract to a Danish research team linked to anti-vaccine controversies and praised by Health Secretary Robert F. Kennedy Jr.
The study planned to follow 14,000 newborns over five years, now, its future is uncertain.
00:37
Guinea-Bissau votes on stronger presidency as military transition nears end
01:08
Guinea-Bissau to vote on constitution expanding presidential powers
01:03
Ebola: DRC receives shipment of more than 16,000 vaccine doses
00:59
DRC Ebola outbreak growing 'exponentially,' UN warns, as deaths exceed 2,500
01:14
DR Congo receives 70,000 Ebola vaccine doses for outbreak response
00:48
First person vaccinated during trial of new Ebola jab